Veradermics (MANE) Price Target Raised to $120 After Positive Trial Data

Citi raised its price target on Veradermics, Incorporated (MANE) to $120 from $85 after the company announced positive topline results from Part A of its Phase 2/3 trial for VDPHL01, an oral minoxidil formulation, in males with pattern hair loss. The trial involved over 500 participants, and Citi noted an increased success odds to 75% while projecting 2035 risk-adjusted peak sales to reach $3 billion, up from the previous estimate of $2 billion. This news positions MANE as a potential leader in FDA-approved treatments for pattern hair loss. As one of the top-performing healthcare stocks in 2026, the updated valuation reflects strong market interest.